Research article

A MICROARRAY GENE ANALYSIS OF PERIPHERAL WHOLE BLOOD IN NORMAL ADULT MALE RATS AFTER LONG-TERM GH GENE THERAPY

YING QIN* and YA-PING TIAN*
Department of Clinical Biochemistry, Chinese PLA General Hospital, 28 Fu-Xing Road, Beijing 100853, P.R. China

Abstract: The main aims of this study were to determine the effects of GH gene abuse/misuse in normal animals and to discover genes that could be used as candidate biomarkers for the detection of GH gene therapy abuse/misuse in humans. We determined the global gene expression profile of peripheral whole blood from normal adult male rats after long-term GH gene therapy using CapitalBio 27 K Rat Genome Oligo Arrays. Sixty one genes were found to be differentially expressed in GH gene-treated rats 24 weeks after receiving GH gene therapy, at a two-fold higher or lower level compared to the empty vector group (p < 0.05). These genes were mainly associated with angiogenesis, oncogenesis, apoptosis, immune networks, signaling pathways, general metabolism, type I diabetes mellitus, carbon fixation, cell adhesion molecules, and cytokine-cytokine receptor interaction. The results imply that exogenous GH gene expression in normal subjects is likely to induce cellular changes in the metabolism, signal pathways and immunity. A real-time qRT-PCR analysis of a selection of the genes confirmed the microarray data. Eight differently expressed genes were selected as candidate biomarkers from among these 61 genes. These 8 showed five-fold higher or lower expression levels after the GH gene transduction (p < 0.05). They were then validated in real-time PCR experiments using 15 single-treated blood samples and 10 control blood samples. In summary, we detected the gene expression profiles of rat peripheral
whole blood after long-term GH gene therapy and screened eight genes as candidate biomarkers based on the microarray data. This will contribute to an increased mechanistic understanding of the effects of chronic GH gene therapy abuse/misuse in normal subjects.

**Key words:** Microarray, Peripheral whole blood, Growth hormone gene therapy, Biomarker genes

**INTRODUCTION**

Growth hormone (GH) therapy has yielded favorable results for childhood growth disorders and adult growth hormone deficiency (GHD) [1, 2]. However, the potential for the application of GH recombinant products in patients with growth hormone deficiency (GHD) is limited by the high cost, attendant risks, and inconvenience of the necessary exogenous s.c. injections. Gene therapy yields a better long-term therapeutic effect than traditional drugs and methods thanks to its alternative approach to the efficient delivery of proteins [3, 4]. However, this also offers the opportunity for the misuse/abuse of GH gene therapy by normal subjects seeking its anabolic or lipolytic effects [5, 6]. Exogenous GH in normal subjects can induce potentially uncontrollable GH hypersecretion, as seen in patients with GH-secreting pituitary adenomas [7]. Moreover, the mechanisms underlying the responses of normal animals to long-term GH gene therapy are not fully understood. The potential toxicity of the gene vector cannot be ignored. In addition, the product of GH gene therapy is the same as the endogenously produced protein, and therefore cannot be detected by a routine urine or blood test. The detection of the associated viral particles might be effective, but would involve muscle biopsies, which are unsuitable for normal individuals [8, 9]. Thus, gene misuse/abuse is more deceptive and even more difficult to detect than conventional drug abuse [5, 6].

The changes in certain genes detected via microarray analysis might decipher the molecular mechanisms involved in physiological and pathological processes in various cells or tissues [10, 11]. Such genes could serve as surrogate markers for the induced modifications, and could obviate the need for muscle biopsies. In this article, we determined the gene expression profiles of rat peripheral whole blood after long-term GH gene therapy using a microarray to evaluate the potential effects of GH gene abuse/misuse in animal models. Eight genes were screened as candidate biomarkers based on the microarray data and validated via real-time qRT-PCR experiments.

**MATERIALS AND METHODS**

**Construction and production of the rAAV2/1 vector containing GH1**

GH1 is a human GH gene (GenBank accession No. NM_000515). A 677-bp segment of GH1, including the 651-bp cds sequence, was cloned from a polymerase chain reaction (PCR) product using the primers 5'-GCCA
GAATTGCCACCATGGCTACAGGCTCCCGG-3' (forward primer) and 5'-CTGCGTCGACGAAGCCACAGCTGCCCTC-3' (reverse primer; the EcoRI and SalI restriction sites are underlined) from the template of a pUC19 plasmid DNA containing the GH1 cds sequence (Xinxiang Medical University, Henan Province, China). The GH1 DNA fragment was digested with SalI/EcoRI and inserted into the SalI/EcoRI sites of the pSNAV2.0 vector (AGTC Gene Technology Co. Ltd., Beijing, China). Large-scale rAAV2/1 production and purification were done as previously described [12]. The viral genome particle titer (approximately 1.0×10^{12} v.g. ml^{-1}) was determined by a quantitative DNA dot blot method [13].

**Animals and sample preparation**

Forty nine Sprague Dawley adult male rats (350 ± 10 g, body weight) were obtained from the Animal Resource Center, General Hospital of PLA, Beijing, China. The rats were randomly divided into three groups. The rats in the GH gene therapy group (GH1 group; n = 23) received 2.5×10^{11} particles of rAAV2/1-CMV-GH1 delivered via an intramuscular injection into both of the hind limbs. The negative control group (NC group; n = 13) received placebo (saline) injections. The rats in the empty vector group (EV group; n = 13) were injected with a single dose of the empty rAAV2/1 vector. Three rats from each group were selected randomly and sacrificed 6 weeks after the injections. The rest of the rats were sacrificed 24 weeks after the injections. Samples of rat peripheral whole blood were collected by cardiac puncture into EDTA vacutainer tubes (Becton Dickinson) and stored at 4ºC until processing (within 8 hours). Once the blood collection was finished, the fresh livers, hearts, kidneys, spleens and quadriceps were quickly removed, snap-frozen between blocks of dry ice and stored at -80ºC.

**Detection of GH1 mRNA expression**

The total RNA was extracted from the quadriceps, livers, kidneys, spleens, and hearts using RNeasy Mini kits (QIAGEN). 5 ng of total RNA was subjected to semi-quantitative RT-PCR using the following primers for the GH1 gene: 5'-ATCCAGGCTTTTGTGACAAA-3' (forward primer) and 5'-TGGAGGGTGTCGGAATAGAC-3' (reverse primer). Thermal cycling was performed as follows: 94ºC for 5 min, 35 cycles at 94ºC for 30 s, 57ºC for 25 s and 72ºC for 30 s, and a final step of 72ºC for 7 min. 6 µl of the 25-µl final PCR volume were analyzed by electrophoresis on 2.5% agarose gels. All of the values were normalized to an internal GAPDH standard.

**Western blot analysis of human GH protein expression**

Soluble protein was extracted from the collected quadriceps, livers, kidneys, spleens, and hearts using a protein extraction reagent (Pierce, USA), and the final protein concentrations were determined using a BCA assay (Pierce, USA) according to the manufacturer’s instructions. Appropriate amounts of the protein extracts were fractionated by electrophoresis in 12% SDS-polyacrylamide gels.
and transferred to nylon membranes. The nylon membranes containing the transferred proteins were pretreated with 1.0% nonfat dried milk in 50 mM Tris (pH 8.0) and then incubated overnight with a primary mouse monoclonal antibody against human growth hormone (1:1000 dilution, NeoMarkers, UK). The membranes were washed and incubated with anti-mouse secondary antibodies and the hGH immunoreactivity was visualized by exposing x-ray film to blots incubated with ECL reagent (Amersham Biosciences, USA). Gray-scale analyses were performed using Image-Pro Plus version 6.0.

**Serum IGF-1 and haematology**
The serum concentrations of IGF-1 (insulin-like growth factor 1) were quantified using specific enzyme-linked immunosorbent assay (ELISA) kits designed for rats (Uscnlife, China) as per the manufacturer’s instructions. Each sample was assayed in duplicate. Total and differential white blood cell (WBC) counts were performed using an ADVIA 120 (Bayer Diagnostics, Switzerland).

**Microarray analysis**
Whole blood RNA was isolated and purified with TRIzol reagent (Invitrogen, Carlsbad, CA, USA) and a NucleoSpin® RNA clean-up kit (Macherey-Nagel, Germany) according to the manufacturer’s instructions. The RNA concentration was evaluated via A260/A280 measurement. Only samples with an A260/A280 between 1.7 and 2.2 were considered suitable for use. The RNA quality was assessed by 1.0% agarose gel electrophoresis.

Five RNA samples from each treatment group were combined into one pool (with equal amounts of RNA from each sample). The untreated controls (samples from the NC group) were used as the baseline expression data. Fluorescence-labeled RNA fragments were produced from 1 μg of RNA by first synthesizing double-stranded cDNA, followed by *in vitro* transcription and fragmentation reactions. A hybridization cocktail, containing the fragmented cRNA, probe array controls, bovine serum albumin and herring sperm DNA, was prepared and hybridized at 42°C for 16 h to the CapitalBio 27 K Rat Genome Oligo Array (CapitalBio, Beijing, China). The arrays were scanned with a confocal LuxScan™ scanner (CapitalBio Corporation, China) and the data from the obtained images was extracted with LuxScan 3.0 software (CapitalBio Corporation, China), employing the LOWESS normalization method. Dye swap experiments were performed to improve the accuracy of the data analysis, and the average ratio from the reciprocal replicates was used to evaluate the expression levels, which were then log transformed and calculated with the CapitalBio® Molecule Annotation System V4.0 (MAS 4.0).

**Real-time quantitative RT-PCR confirmation**
Fifteen candidate genes were randomly selected from the differently expressed genes that showed 2-fold higher or lower expression levels (p < 0.05) and
Tab. 1. The list of primer sets used for real-time PCR validation.

| Gene     | Accession No. | Primer sequence 5'→3' | Amplification size (bp) |
|----------|---------------|------------------------|-------------------------|
| Rp113    | BC086577      | F: GAATGCGTCGAGTGCTC   | 183                     |
|          |               | R: CTTCGCTCCAGCGGATG   |                         |
| Gpr109a  | AB103062      | F: GCTCCCTCTCCACACAC   | 174                     |
|          |               | R: CGAGGCAACGCGGTGAT   |                         |
| Hexim1   | BC087133      | F: GAAAGCGTGTAGGAAGAG | 161                     |
|          |               | R: CAGAGGCAAGGCCGAT    |                         |
| Nfkbia   | XM_343065     | F: GCTGGCGAAGTCTAGGA   | 218                     |
|          |               | R: TGCTGTTGCTAAGTATA   |                         |
| G0s2     | H32223        | F: GATGGAAAGTGTGCAGAG | 157                     |
|          |               | R: AGCTTGAAAGCGATGCA   |                         |
| Ddit3    | BC100664      | F: GAAACGGAACAGAGTGTG | 255                     |
|          |               | R: TGATGGTGCTGGTACT    |                         |
| Ets1     | L20681        | F: GCTCCATTGTGTCCAGAG | 247                     |
|          |               | R: CAGAGAAGCGCATGC     |                         |
| Lyar     | BC079008      | F: GAA GCGGAAAGACACTC | 217                     |
|          |               | R: GCGATGGTACTGACCTATA |                      |
| RT1-Db1  | NM_001008884  | F: TGACAGTGGGAGAAGCCCT | 298                     |
|          |               | R: TCTATGCAGACGACTTGG |                         |
| Ncoa4    | NM_001034008  | F: GCTTGTTGCTCTCTTCTTA| 263                     |
|          |               | R: CAGCTGTACCTTTCCAGCT |                      |
| Mylk2    | J03886        | F: GGGCTACCACCTTCTGGT | 236                     |
|          |               | R: CGCACGCTCTCACTACTCT |                     |
| RT1-T24-1| NM_001008858  | F: CCCAGGGTTTCAACCACAC | 107                     |
|          |               | R: GCTGAAGCCTGCTCCTGT |                         |
| Plekbb1  | BG666307      | F: GAATGGGACTCACAAGAGA | 185                     |
|          |               | R: CATGCTGCTTATCCAGC  |                         |
| Pttg1    | U73030        | F: GAA AAGCAGTGAGAAGTAG| 200                     |
|          |               | R: AGTGAGATCCTGTCCTCTCA|                       |
| Ly1      | BC081864      | F: GAGAGCTGACCTGGAAGT | 167                     |
|          |               | R: CACCTGTTTGTGTCTACCT |                     |
| β-Actin  |               | F: GTACCCAGGCATTGGCTGAC| 169                     |
|          |               | R: CTCCTGCTTGGCTGATCCACATC |               |

validated via real-time quantitative RT-PCR experiments. The primer sequences are listed in Tab. 1. The real-time quantitative RT-PCR was performed using
a LightCycler-FastStart DNA Master SYBR Green I Kit (Roche Applied Science) according to the manufacturer’s instructions. The program was as follows: initiation with 10 minutes of denaturation at 95ºC, followed by 40 cycles of amplification with 15 s of denaturation at 95ºC, 5 s at 56ºC for annealing, and 15 s of extension at 72ºC. The melting curves were produced and 1.5% agarose gel electrophoresis was performed to validate the specificity of the amplified products. The comparative threshold cycle (CT) method was used to calculate the degree of amplification. β-actin was used as a reference control gene to normalize the expression value of each gene. The experiment was performed in triplicate for each gene, and the average expression value was computed for subsequent analysis. The results were compared using the 2^ΔΔCT method [14] and are expressed as log2 means ± SD. The 8 genes that showed 5-fold higher or lower expression levels (p < 0.05) in the GH1 group compared with the EV group were selected as the gene panel to distinguish the GH therapy group from the control groups. We examined the relative mRNA ratios of these genes in 15 single rat whole blood samples from the GH1 group, using 5 whole blood samples from the NC and EV group rats mixed as controls via real-time qRT-PCR. The primer sequences are listed in Tab. 2.

Tab. 2. The primer sets for the candidate biomarkers used for real-time PCR validation.

| Gene     | Accession No. | Primer sequence 5'→3'                        | Amplification size (bp) |
|----------|---------------|----------------------------------------------|-------------------------|
| Pla2g2a  | NM_031598     | F:GGGAAGGAAAGCGCCTCTCAAGTTAT R:CACATCCACGTTTTCTCCAGACGTT | 139                     |
| Gpr109a  | AB103062      | F: GCTCCTCTACAAACACAACAG R: CAGAAGGCAACGGGTGATG | 174                     |
| Hexim1   | BC087133      | F: GAAGCTGTTGAGGAAGACG R: CACTTCTCCAGCTCCAGGTAC | 161                     |
| Nfkbia   | XM_343065     | F: GCTGGGCAAGAGTTCTAGGAAT R: TGCTGTGGTCTAAAGTATAAC | 218                     |
| Ilk      | NM_133409     | F: AGGGCGCTTTTGGCTGAGCTTTCTCA R: TGCTAAAAGCTTGGTCGTTTGAGAG | 156                     |
| Birc3    | NM_023987     | F: AAGCTTTCCTCACACCTTGTA A R: TAGAATCTGCTTGGCCAGCTCT | 168                     |
| Rap1b    | NM_134346     | F: CGGACAAAGGCCCTGCTGTTTCTTAA R: TGAACCTTGGTCTCCAGCGACAAC | 174                     |
| Ptg1     | BC081816      | F: TGTGTTGACTCGTGAAGAGGA R: TGAGCTGCGAAGAAATAGGCCACTCA | 146                     |
| β-Actin  |               | F: GTACCCAGGCATGCTGACA R: CTCCTGCTTGATCCACATC | 169                     |
**Statistical analyses**

The data was analyzed by ANOVA with post hoc analysis using Bonferroni’s method in the SPSS statistical package 13.0 (SPSS Inc., Chicago, IL, USA), and was considered statistically significant at p < 0.05.

A receiver operating characteristic (ROC) curve analysis was done to determine whether the gene panel could discriminate the GH therapy group from the control groups. The area under the receiver operating characteristic curve (AUC) was calculated, using binary logistic regression analysis in SPSS 13.0. The results are reported as the SE of regression (SE), significance (Sig.), 95% confidence interval (95% CI), positive and negative predictive values (PPV/ NPV), true positive rate (TRP), and false positive rate (FRP).

**RESULTS**

**Animal models and verification of GH1 transduction in vivo**

A 215-bp band of the GH1 gene was detected by semi quantitative RT-PCR in the injected quadriceps of rats after the injection of rAAV2/1-CMV-GH1. There was almost no expression of GH1 in the liver, heart, kidneys and spleen in any group in this study prior to the injection of the viral vector or saline control. The expression of GH1 mRNA was sustained for almost six months (Fig. 1).

![Fig. 1](image-url)

Fig. 1. The relative levels of GH1 mRNA expression in the skeletal muscle of the hind limbs, 6 and 24 weeks after the injection of the rAAV2/1 virus containing the GH1 expression vector. **p < 0.01 versus the NC group. The error bars correspond to the standard deviation (SD). NC – negative control rats; EV – group rats; GH1 (6W) – the GH1 group rats 6 weeks after the injection of rAAV2/1-CMV-GH1; GH1 (24W) – the GH1 group rats 24 weeks after the injection of rAAV2/1-CMV-GH1. The number of samples for each group is 3.
Western blot analysis demonstrated the presence of the 22-kDa secreted hGH protein in the quadriceps of the GH1 group rats, and showed the specific GH1 expression in the GH1 group rats, a trend that was confirmed by the results of the RT-PCR experiments (Fig. 2). The subsequent experiments were based on the validation of the specific *GH1* gene expression in the muscles of the animal models.

**Fig. 2.** A Western blot analysis of the relative hGH expression levels in the skeletal muscle of the hind limbs 6 and 24 weeks after the injection of rAAV2/1-CMV-GH1. **p < 0.01** versus the EV group. The error bars correspond to the standard deviation (SD). NC – negative control rats; EV – group rats; GH1 (6 W) – GH1 group rats 6 weeks after the injection; GH1 (24 W) – GH1 group rats 24 weeks after the injection of rAAV2/1-CMV-GH1. The number of samples for each group is 3.

**Fig. 3.** The serum concentrations of IGF-1 24 weeks after the injection. *p < 0.05* versus the EV group. The error bars correspond to the standard deviation (SD).
The serum levels of IGF-I were consistently significantly higher in the GH1 group during the 24 weeks after the injection compared with the levels for the NC and EV groups (p < 0.05, Fig. 3). There were no notable differences in the serum levels of IGF-I between the NC and EV groups.

Tab. 3 shows that the white blood cell (WBC), monocyte and neutrophil counts in the peripheral blood in the GH1 group increased significantly 6 weeks after the injection of GH1. The increase in the WBC count was mainly due to the increase in the neutrophil count.

| Group      | Mean value ± SD for the various groups |
|------------|---------------------------------------|
|            | WBC (10^3 µl^-1) | Lymphocyte counts (10^3 µl^-1) | Monocyte counts (10^3 µl^-1) | Neutrophil counts (10^3 µl^-1) |
| EV         | 7.46 ± 1.15       | 5.43 ± 1.14                   | 0.21 ± 0.05                  | 1.26 ± 0.15                   |
| NC         | 7.17 ± 1.24       | 5.28 ± 1.21                   | 0.19 ± 0.04                  | 1.21 ± 0.18                   |
| GH1 (6W)   | 9.62 ± 1.10*      | 5.99 ± 1.23                   | 0.49 ± 0.06*                 | 2.37 ± 0.45*                 |
| GH1 (24W)  | 7.88 ± 1.29       | 5.66 ± 1.28                   | 0.24 ± 0.06                  | 1.58 ± 0.22                   |

Global changes in the whole blood gene expression after injection

We detected 107 genes that were upregulated and 482 genes that were downregulated in the EV group compared with the NC group, while 168 genes were upregulated and 331 genes were downregulated in the GH1 group compared with the EV group. 8 of the differentially expressed genes that showed 2-fold higher or lower expression levels in the EV group satisfied the criterion of p < 0.05 compared to the NC group. Of these 8 altered genes, 6 were upregulated and 2 were downregulated. Sixty one genes showed 2-fold higher or lower expression levels in the GH1 group (p < 0.05) relative to the EV group. Twenty five of the 61 genes were upregulated and 35 were downregulated.

The functional classification of each altered gene was obtained by searching the Gene ontology (GO) database in the CapitalBio® Molecule Annotation System V4.0 (MAS 4.0). The distributions of the functions of the differently expressed genes in the GH1 group rats 24 weeks after the injection of rAAV2/1-CMV-GH1 compared with the EV group are shown in Fig. 4. These genes were predominantly in the molecular function, regulation of biological process, and cellular component classes. The biological interpretation of the gene clusters was completed using Ingenuity Pathways Analysis (IPA) and the KEGG databases in the MAS 4.0 software package.

As shown in Tab. 4, in the GH1 group rats 24 weeks after the injection of rAAV2/1-CMV-GH1, the genes that were upregulated or downregulated by more than 2-fold when compared with the EV group (p < 0.05) were associated
with the Jak-STAT signaling pathway, cardiac hypertrophy, the insulin signaling path-
way, type I diabetes mellitus, the adipocytokine signaling pathway, the cell cycle, 
arachidonic acid metabolism, glycerophospholipid metabolism, carbon fixation, 
cytokine-cytokine receptor interaction, the MAPK signaling pathway, 
angiogenesis, oncogenesis, apoptosis, cell adhesion molecules (CAMs), and the Wnt signaling pathway. Tab. 5 defines the immune networks in the peripheral blood of the GH1 group 24 weeks after the injection of GH1. These were identified by IPA when compared to the EV group (p < 0.05). Tab. 6 shows the genes that were differently expressed by more than 2-fold in the EV group rats compared with the NC group rats (p < 0.05).

Fig. 4. The distributions of the functions and the expression levels of the genes that were differently expressed in the GH1 group rats 24 weeks after the injection of rAAV2/1-CMV-GH1. The number of samples is 5.

Tab. 4. The genes that were upregulated or downregulated by 2-fold or higher in the peripheral whole blood of the GH1 group rats 24 weeks after the injection relative to the EV group rats (p < 0.05).

| Gene symbol | Gene function and gene description | Accession No. | Fold change |
|-------------|-----------------------------------|---------------|-------------|
| Jak-STAT signaling pathway | | | |
| Ptpn6 | Tyrosine-protein phosphatase non-receptor type 6 | U77038 | 2.6↑ |
| Ifngr | Interferon gamma receptor 2 | XM_340967 | 2.1↓ |
| Pim1 | Proto-oncogene serine/threonine-protein kinase Pim-1 | XM_234263 | 2.1↓ |
| Myc | Myelocytomatosis viral oncogene homolog | NM_012603 | 3.2↑ |
| Il4ra | Interleukin-4 receptor alpha chain precursor | AB015746 | 2.1↑ |
| Jak2 | Janus kinase 2 | U13396 | 2.3↓ |
| Sos2 | Son of sevenless homolog 2 | XM_234263 | 2.1↑ |
| Gene symbol | Gene function and gene description                                      | Accession No. | Fold change |
|-------------|------------------------------------------------------------------------|---------------|-------------|
| Gsk3b       | Glycogen synthase kinase 3 beta                                        | X73653        | 2.3↓        |
| Pygl        | Liver glycogen phosphorylase                                           | BC070901      | 2.1↓        |
| Prkar2b     | Protein kinase, cAMP dependent regulatory, type II beta                | M12492        | 2.3↓        |
| Sos2        | Son of sevenless homolog 2                                             | XM_234263     | 2.1↑        |
| RT1-Ba      | RT1 class II, locus Ba                                                 | X14879        | 4.3↓        |
| RT1-T24-1   | RT1-149 protein                                                        | NM_001008858  | 3.3↓        |
| RT1-Db1     | RT1 class II histocompatibility antigen, D-1 beta chain precursor      | NM_001008884  | 3.2↓        |
| Mylk2       | Myosin light chain kinase 2, skeletal/cardiac muscle                   | J03886        | 2.2↓        |
| RT1-S3      | RT1-149 protein                                                        | NM_001008826  | 3.3↓        |
| Hexim1      | Cardiac lineage protein 1 (Clp1)                                      | BC087133      | 5.0↑        |
| Nfkb1       | Nuclear factor NF-kappa-B p105 subunit                                 | XM_342346     | 4.3↓        |
| Prkcq       | PKC theta protein                                                      | XM_341553     | 2.1↓        |
| Jak2        | Tyrosine-protein kinase JAK2                                           | U13396        | 2.8↑        |
| Gpr109a     | Nicotinic acid receptor                                                | AB103062      | 17.2↑       |
| Nfkbia      | NF-kappaB inhibitor alpha                                              | XM_343065     | 3.2↓        |
| Pla2g2a     | Phospholipase A2                                                       | NM_031598     | 43.1↓       |
| Ptgs1       | Prostaglandin G/H synthase 1 precursor                                 | BC081816      | 5.8↓        |
| Alox15      | Arachidonate12-lipoxygenase, leukocyte-type                            | NM_031010     | 3.1↓        |
| Hagh        | Hydroxyacylglutathione hydrolase                                      | BC097301      | 2.1↓        |
| Csflr       | Colony-stimulating factor 1 receptor                                   | NM_001029901  | 2.1↓        |
| Ccr7        | Chemokine (C-C motif) receptor 7                                       | NM_199489     | 2.1↓        |
| Ltrb        | Lymphotoxin B receptor                                                 | BC085880      | 2.4↓        |
| Il4ra       | Interleukin-4 receptor alpha chain precursor                           | AB015746      | 2.1↓        |
| Pla2g2a     | Phospholipase A2, membrane-associated precursor                         | NM_031598     | 43.1↓       |
| Pafah1b2    | Platelet-activating factor acetylhydrolase IB beta subunit             | NM_022387     | 3.4↓        |
| Csflr       | Colony-stimulating factor 1 receptor                                   | NM_001029901  | 2.1↓        |
| Ccr7        | Chemokine (C-C motif) receptor 7                                       | NM_199489     | 2.1↓        |
| Ltrb        | Lymphotoxin B receptor                                                 | BC085880      | 2.4↓        |
| Gene symbol | Gene function and gene description                                      | Accession No. | Fold change |
|------------|------------------------------------------------------------------------|---------------|-------------|
| Aldoa      | Fructose-bisphosphate aldolase A                                       | BC064440      | 2.1↑        |
|            | **Carbon fixation**                                                    |               |             |
|            | **Cell cycle**                                                         |               |             |
|            | **Angiogenesis-, oncogenesis- & apoptosis-related**                    |               |             |
| S100a9     | Calgranulin B                                                          | CB728702      | 3.4↑        |
| Cxcl1      | Growth-regulated alpha protein precursor                               | NM_030845     | 3.3↑        |
| Ccn1l      | Cyclin-L1                                                              | BC085686      | 3.3↑        |
| Nfkbia     | NF-kappaB inhibitor alpha                                               | XM_343065     | 3.2↑        |
| Pena       | Proliferating cell nuclear antigen                                      | NM_022381     | 3.2↑        |
| G0s2       | G0/G1 switch gene 2                                                    | H32223        | 3.2↑        |
| Ddit3      | DNA-damage inducible transcript 3                                      | BC100664      | 3.0↑        |
| Ets1       | C-ets-1 protein                                                        | L20681        | 2.1↑        |
| Rpl13      | Ribosomal protein L13                                                  | BC086577      | 2.0↑        |
| Ier2       | Immediate early response 2                                             | BC061717      | 3.0↑        |
| Ier3       | Immediate early response 3                                             | BC099831      | 3.0↑        |
| Ier5       | Immediate early response 5                                             | BE113744      | 3.2↑        |
| Lyar       | Cell growth-regulating nucleolar protein                               | BC079008      | 2.2↑        |
| Il1b       | Interleukin 1 beta                                                     | BC091141      | 4.0↑        |
| Pena       | Proliferating cell nuclear antigen                                      | NM_022381     | 3.2↑        |
| Cdc25b     | Cathepsin B precursor                                                  | D16237        | 3.3↑        |
| Ywhah      | 14-3-3 protein eta.                                                    | BC081825      | 2.1↑        |
|            | **Cell adhesion molecules (CAMs)**                                     |               |             |
| Ilk        | Integrin-linked kinase                                                 | NM_133409     | 5.5↓        |
|            | **MAPK signaling pathway**                                             |               |             |
| Cdc25b     | M-phase inducer phosphatase 2                                          | D16237        | 2.3↓        |
| Map2k3     | Map2k3_predicted protein                                               | XM_239239     | 2.2↑        |
| Nfkb1      | Nuclear factor NF-kappa-B p105 subunit                                 | XM_342346     | 4.3↑        |
| Rap1a      | Ras-related protein Rap-1A                                             | BC083813      | 3.1↑        |
| Pla2g2a    | Phospholipase A2                                                       | NM_031598     | 43.1↓       |
| Sos2       | Son of sevenless homolog 2                                             | XM_234263     | 2.1↑        |
| Rap1b      | Ras-related protein Rap-1b                                             | NM_134346     | 12.2↓       |
|            | **Wnt signaling pathway**                                              |               |             |
| Nfkb1      | Nuclear factor NF-kappa-B p105 subunit                                 | XM_342346     | 2.7↑        |
| Birc3      | Inhibitor of apoptosis protein 1                                       | NM_023987     | 7.8↑        |
| Cd3g       | CD3 antigen, gamma polypeptide                                         | XM_217136     | 2.5↑        |

↑ upregulated genes, ↓ downregulated genes
Tab. 5. The GH immune networks in the peripheral blood of the GH1 group 24 weeks after the injection of GH1 relative to the EV group rats.

| Gene symbol | Gene function and gene description | Accession No. | Fold change |
|-------------|-----------------------------------|---------------|-------------|
| Hspa8       | Heat shock cognate 71-kDa protein | BC061547      | 2.3↑        |
| Hspa5       | 78-kDa glucose-regulated protein precursor | BC062017      | 4.0↑        |
| RT1-T24-1   | RT1-149 protein                  | NM_001008858  | 3.4↓        |
| RT1-Db1     | RT1 class II histocompatibility antigen, D-1 beta chain precursor | NM_001008884  | 3.2↓        |
| RT1-S3      | RT1-149 protein                  | NM_001008826  | 3.3↓        |
| Ctsb        | Cathepsin B precursor            | NM_001008858  | 3.3↓        |
| Cd74        | CD74 antigen                      | NM_013069     | 2.1↓        |

**Antigen processing and presentation**

| Gene symbol | Gene function and gene description | Accession No. | Fold change |
|-------------|-----------------------------------|---------------|-------------|
| Fos         | Proto-oncogene protein c-fos      | NM_022197     | 3.5↑        |
| Ptpn6       | Tyrosine-protein phosphatase non-receptor type 6 | U77038       | 2.6↑        |
| Nfkbia      | NF-kappaB inhibitor alpha          | XM_343065     | 3.2↓        |
| Nfkb1       | Nuclear factor NF-kappa-B p105 subunit | XM_342346     | 4.3↓        |
| Cdt81       | CD 81 antigen                     | BC060583      | 2.2↓        |
| Ctla4       | Cytotoxic T-lymphocyte-associated protein 4 | U37121       | 2.4↑        |

**B-cell receptor signaling pathway**

↑ upregulated genes, ↓ downregulated genes

Fig. 5. Real-time RT-PCR experiments confirmed the microarray data and showed the differentially expressed genes including Rpl13, Gpr109a, Hexim1, Nfkbia, G0s2, Ddit3, Ets1, RT1-T24-1, RT1-Db1, Mylk2 and Lyar in the GH1 group; and Ncoa4, Plekhb1, Ptgtl and Lyll in the EV group 24 weeks after the injection. The fold change is displayed relative to normal adult male rat blood samples. The error bars correspond to the standard deviation (SD). The number of sample for each group is 5.
Real-time quantitative RT-PCR was used to verify the expression levels of 15 differently expressed genes selected on the basis of their functional properties and the fold change in their expression levels (at least 2-fold higher or 2-fold lower) among the three different groups at a significance level of \( p < 0.05 \) (Fig. 5). Although there were small differences in the fold-change values between the microarray and the real-time quantitative RT-PCR, the real-time quantitative RT-PCR results agreed with the microarray data.

Tab. 6. Genes that were upregulated or downregulated by 2-fold or higher in the peripheral whole blood of the EV group rats at 24 weeks relative to the NC control rats \((p < 0.05)\).

| Gene symbol | Gene function and gene description | Accession No. | Fold change |
|-------------|-----------------------------------|---------------|-------------|
| Lyll        | Lymphoblastic leukemia-derived sequence 1 | BC081864 | 2.7↑ |
| Pttg1       | Securin (pituitary tumor-transforming protein 1). | U73030 | 2.6↑ |
| Plekhb1     | Pleckstrin homology domain-containing family B member 1 | BG666307 | 2.3↑ |
| Rps29       | 40S ribosomal protein S29 | BF557769 | 2.2↑ |
| Pcna        | Proliferating cell nuclear antigen | NM_022381 | 2.2↑ |
| Ncoa4       | Beta-microseminoprotein precursor | NM_001034008 | 2.0↑ |

**Antigen processing and presentation**

| Gene symbol | Gene function and gene description | Accession No. | Fold change |
|-------------|-----------------------------------|---------------|-------------|
| RT1-T24-1   | RT1-149 protein | NM_001008858 | 2.1↓ |
| CtsS        | Cathepsin S precursor | BC059142 | 2.1↓ |
| RT1-Ba      | RT1 class II, locus Ba | X14879 | 4.2↓ |

**Cell adhesion molecules (CAMs)**

| Gene symbol | Gene function and gene description | Accession No. | Fold change |
|-------------|-----------------------------------|---------------|-------------|
| RT1-T24-1   | RT1-149 protein | NM_001008858 | 2.1↓ |
| Ppp1cc      | Serine/threonine protein phosphatase PP1-gamma catalytic subunit | XM_346435 | 2.0↓ |

↑ upregulated genes, ↓ downregulated genes

**Potential biomarker genes for the detection of GHI abuse/misuse**

Eight genes that showed at least 5-fold higher or lower expression levels between the GH1 group and the controls at \( p < 0.05 \) were selected as candidate biomarker genes for the detection of GH gene therapy abuse/misuse. We studied their expressions using real-time PCR in a total of 15 rat whole blood samples from the GH1 group, 5 from the NC group, and 5 from the EV group using \( \beta \)-actin mRNA as an endogenous quantity control. To correctly assess this issue, we omitted the 15 rats (5 from each group) on which we had done the original microarray analysis. The 8 genes showed considerable concordance between the array and the quantitative real-time data in each sample (Tabs 4, 5; Fig. 6). The nonparametric receiver operator characteristic (ROC) analysis was performed based on the PPV and NPV to determine whether the gene panel could discriminate the GH therapy group from the control groups. For each gene, the
area under the curve (AUC) and its associated 95% confidence interval (CI) were reported (Tab. 7). The ROC curve is shown in Fig. 7.

The AUC for the 8-gene panel was 1.00. Tab. 7 and Fig. 7 together show that the ROC analysis of the 8-gene panel could distinguish the GH1-treated rats from the control rats.

Fig. 6. The validation of candidate biomarker genes by real-time PCR. The fold change is displayed relative to normal adult male rat blood samples. The error bars correspond to the standard deviation (SD). The number of samples for each group is 5.

Fig. 7. The receiver operator characteristic curves (ROC) for the gene panel (8 potential biomarker genes) for GH1 abuse/misuse detection.
Tab. 7. The receiver operator characteristic (ROC) analysis predicting GH1 abuse/misuse based on the PPV and NPV.

| Gene     | AUC  | PPV   | NPV   | SE  | Sig.  | 95% CI      |
|----------|------|-------|-------|-----|-------|-------------|
| Gpr109a  | 0.93 | 86.7% | 100.0%| 0.06| 0.00  | (0.82, 1.04)|
| Hexim1   | 0.89 | 93.3% | 100.0%| 0.07| 0.01  | (0.76, 1.02)|
| Plag2a   | 0.91 | 86.7% | 100.0%| 0.09| 0.01  | (0.78, 1.04)|
| Nfkbia   | 0.83 | 80.0% | 100.0%| 0.04| 0.06  | (0.66, 1.00)|
| Birc3    | 0.96 | 93.3% | 100.0%| 0.04| 0.00  | (0.88, 1.04)|
| Rap1b    | 1.00 | 100.0%| 100.0%| 0.00| 0.00  | (1.00, 1.00)|
| Ptg1     | 0.97 | 86.7% | 100.0%| 0.03| 0.00  | (0.91, 1.03)|
| Ilk      | 0.96 | 93.3% | 100.0%| 0.04| 0.00  | (0.89, 1.03)|

DISCUSSION

Thymic function can be significantly enhanced by GH therapy to produce new T-lymphocyte cells and may therefore reverse some T-lymphocyte dysfunction. Our microarray experiments showed that Ctsb, Hspa8, RT1-Dd1, RT1-S3, RT1-T24-1 Fos, Ptpn6, Nfkbia, Nfkb1, Cd81, Ctla4 and Hspa5, which are involved in the T-cell receptor signaling pathway, B-cell receptor signaling pathway, and antigen processing and presentation, were expressed differentially, at a significance level of p < 0.05. Furthermore, GH gene therapy was found to significantly increase the absolute number of WBCs and neutrophils. The above results indicated that the changes in the immune networks regulated by GH could improve bodily immune function, which raises the possibility that rhGH may form part of an immune-based therapeutic programme tailored to the treatment of HIV/AIDS, cystic fibrosis (CF), inflammatory bowel disease (IBD), juvenile rheumatoid arthritis (JRA) and chronic renal insufficiency (CRI). However, the altered immunity suggested that there is a potential risk of the development of anti-GH antibodies that could blunt the effect of a high level of exogenous GH in animals. Meanwhile, RT1-T24-1, Ctsb and RT1-Ba were found to be downregulated more than 2-fold in the EV group, which might reflect changes in the cellular immune responses arising from the viral vector itself.

GH acts through its receptor on the cell surface, which is a cytokine class I receptor with multiple tyrosines on the intracellular domain. Binding the hormone to the receptor induces receptor tyrosine phosphorylation with intracellular signaling through a number of pathways, such as the signal transducer and activator of transcription 5 (STAT5), mitogen-activated protein kinase (MAPK), phosphoinositide-3 kinase (PI3K), and Janus kinase 2 (JAK2), which yield differential gene expression and changes in the physiological response [15, 16]. Here, we detected the changes in the blood gene expression between GH1-treated rats and control rats using the CapitalBio 27 K Rat Genome Oligo Array (CapitalBio, Beijing, China), which comprises 26,962 70-mer oligo probes from the Operon Rat Genome Version 3.0.5 library, representing
27,044 gene transcripts corresponding to over 22,012 rat genes. The results suggested that the differentially expressed genes were involved in pathobiologically and therapeutically relevant processes such as angiogenesis, oncogenesis, apoptosis, cardiac hypertrophy, hematopoietic cell lineage, type I diabetes mellitus, carbon fixation, the cell cycle, cytokine-cytokine receptor interaction, focal adhesion, glycerophospholipid metabolism, and signaling pathways. The results demonstrated that exogenous GH gene expression in normal subjects is likely to induce cellular changes in the metabolism, signalling pathways and immunity. Of the 8 candidate biomarker genes, Pla2g2a, Gpr109a and Rap1b showed over 10-fold higher or lower gene expression levels in the GH1 group rats than in the NC controls.

Pla2g2a, which encodes the Pla2 group II A secreted phospholipase A2, showed an over 40-fold lower expression in whole blood after the injection of rAAV2/1-CMV-GH1 than in the NC controls (p < 0.05). Pla2g2a plays diverse roles in human diseases, including colon cancer, coronary artery disease and inflammation [17-21]. The mRNA expression of Gpr109a showed an over 10-fold increase in rat whole blood samples after the injection of rAAV2/1-CMV-GH1 (p < 0.05). It is a G-protein-coupled receptor for nicotinic acid, and is most noted for its anti-lipolytic effects in adipocytes [22, 23]. Rap1b, an abundant small GTPase in the platelets, showed an over 10-fold lower expression. The results of recent studies suggest that Rap1b is involved in a common critical step required for platelet activation [24]. The above results demonstrated that although there was no certain evidence of tumorigenesis in our research, the changes in the gene expressions in whole blood induced by an elevated GH concentration could increase the risks of colon cancer and other diseases.

In this study, we were limited by our small sample sizes. Furthermore, the molecular mechanisms involved in GH gene therapy abuse/misuse are complex. Gene expression may be confounded by the duration and dosage of the rAAV2/1-CMV-GH1 treatment. In addition, using whole blood RNA could not rule out the heterogeneity of the cell population or the potential diversity of cell-specific responses, though we could not detect any common abnormality in the CBC and leukocyte subpopulations of the studied cases.

Acknowledgments. We would like to thank the staff of the department for their support and suggestions. This study was supported by research grants from the National Science Foundation for Post-doctoral Scientists of China (No. 20080431363) and the National Natural Science Foundation of China to Ya-ping Tian (No. 20635002).
REFERENCES

1. Götherström, G., Elbornsson, M., Stibrant-Sunnerhagen, K., Bengtsson, B.A., Johannsson, G. and Svensson J. Ten years of growth hormone (GH) replacement normalizes muscle strength in GH deficient adults. J. Clin. Endocrinol. Metab. 94 (2008) 809-816. DOI: 10.1210/jc.2008-1538.

2. Ayuk, J. and Sheppard, M.C. Growth hormone and its disorders. Postgrad. Med. J. 82 (2006) 24-30. DOI: dx.doi.org/10.1136/pgmj.2005.036087.

3. Rivera, V.M., Ye, X., Courage, N.L., Sachar, J., Cerasoli, F., Wilson, J.M. and Gilman, M. Long-term regulated expression of growth hormone in mice after intramuscular gene transfer. Proc. Natl. Acad. Sci. USA. 96 (1999) 8657-8662. DOI: dx.doi.org/10.1073/pnas.96.15.8657.

4. Büning, H., Perabo, L., Coutelle, O., Quadt-Humme, S. and Hallek, M. Recent developments in adeno-associated virus vector technology. J. Gene Med. 10 (2008) 717-733. DOI: dx.doi.org/10.1002/jgm.1205.

5. Filipp, F. Is science killing sport? Gene therapy and its possible abuse in doping. EMBO Rep. 8 (2007) 433-435. DOI: dx.doi.org/10.1038/sj.embor.7400968.

6. Harridge, S.D. and Velloso, C.P. Gene doping. Essays Biochem. 44 (2007) 125-138. DOI: dx.doi.org/10.1042/BSE0440125.

7. Melmed, S. Medical progress: Acromegaly. N. Engl. J. Med. 355 (2006) 2558-2573. DOI: dx.doi.org/10.1056/NEJMra062453.

8. McCrory, P. Super athletes or gene cheats? Br. J. Sports Med. 37 (2003) 192-193. DOI: dx.doi.org/10.1136/bjsm.37.3.192.

9. Wells, D.J. Gene doping: the hype and the reality. Br. J. Pharmacol. 154 (2008) 623-631. DOI: dx.doi.org/10.1038/bjp.2008.144.

10. Schena, M., Shalon, D., Davis, R.W. and Brown, P.O. Quantitative monitoring of gene expression patterns with a complementary DNA microarray. Science 270 (1995) 467-470. DOI: 10.1126/science.270.5235.467.

11. Chen, B.P., Li, Y.S., Zhao, Y., Chen, K.D., Li, S., Lao, J., Yuan, S., Shyy, J.Y. and Chien, S. DNA microarray analysis of gene expression in endothelial cells in response to 24-h shear stress. Physiol. Genomics 7 (2001) 55-63.

12. Yan, H., Guo, Y.H., Zhang, P., Zu, L.Y., Dong, X.Y., Chen, L., Tian, J.W., Fan, X.L., Wang, N.P., Wu, X.B. and Gao, W. Superior neovascularization and muscle regeneration in ischemic skeletal muscles following VEGF gene transfer by rAAV1 pseudotyped vectors. Biochem. Biophys. Res. Commun. 336 (2005) 278-287. DOI: dx.doi.org/10.1016/j.bbrc.2005.08.066.

13. Snyder, R., Xiao, X. and Samulski, R.J. Production of recombinant adenovaseassociated viral vectors. in: Current Protocols in Human Genetics (Smith, D. Ed.), Wiley, New York, 1996, 12.1.1-12.2.23.

14. Livak, K.J. and Schmittgen, T.D. Analysis of relative gene expression data
using real-time quantitative PCR and the $2^{\Delta \Delta CT}$ method. Methods 25 (2001) 402-408. DOI: dx.doi.org/10.1006/meth.2001.1262.

15. Herrington, J. and Carter-Su, C. Signaling pathways activated by the growth hormone receptor. Trends Endocrinol. Metab. 12 (2001) 252-257. DOI: dx.doi.org/10.1016/S1043-2760(01)00423-4.

16. Lichanska, A.M. and Waters, M.J. How growth hormone controls growth, obesity and sexual dimorphism. Trends Genet. 24 (2007) 41-47. DOI: dx.doi.org/10.1016/j.tig.2007.10.006.

17. Cormier, R.T., Hong, K.H., Halberg, R.B., Hawkins, T.L., Richardson, P., Mulherkar, R., Dove, W.F. and Lander, E.S. Secretory phospholipase Pla2g2a confers resistance to intestinal tumorigenesis. Nat. Genet. 17 (1997) 88-91. DOI: dx.doi.org/10.1038/ng0997-88.

18. Kugiyama, K., Ota, Y., Sugiyama, S., Kawano, H., Doi, H., Soejima, H., Miyamoto, S., Ogawa, H., Takazoe, K. and Yasue, H. Prognostic value of plasma levels of secretory type II phospholipase A2 in patients with unstable angina pectoris. Am. J. Cardiol. 86 (2000) 718-722. DOI:10.1016/S0002-9149(00)01069-9.

19. Fijneman, R.J., Peham, J.R., van de Wiel, M.A., Meijer, G.A., Matise, I., Veliech, A. and Cormier, R.T. Expression of Pla2g2a prevents carcinogenesis in Muc2-deficient mice. Cancer Sci. 99 (2008) 2113-2119. DOI: dx.doi.org/10.1111/j.1349-7006.2008.00924.x.

20. Hong, K.H., Bonventre, J.C., O’Leary, E., Bonventre, J.V. and Lander, E.S. Deletion of cytosolic phospholipase A (2) suppresses Apc(Min)-induced tumorigenesis. Proc. Natl. Acad. Sci. U.S.A. 98 (2001) 3935-3939. DOI: dx.doi.org/10.1073/pnas.051635898.

21. Touqui, L. and Alaoui-El-Azher, M. Mammalian secreted phospholipases A2 and their pathophysiological significance in inflammatory diseases. Curr. Mol. Med. 1 (2001) 739-754. DOI: dx.doi.org/10.2174/1566524013363258.

22. Pike, N.B. Flushing out the role of GPR109A (HM74A) in the clinical efficacy of nicotinic acid. J. Clin. Invest. 115 (2005) 3400-3403. DOI: dx.doi.org/10.1172/JCI27160.

23. Martin, P.M., Ananth, S., Cresci, G., Roon, P., Smith, S. and Ganapathy, V. Expression and localization of GPR109A (PUMA-G/HM74A) mRNA and protein in mammalian retinal pigment epithelium. Mol. Vis. 15 (2009) 362-372.

24. Chrzanowska-Wodnicka, M., Smyth, S.S., Schoenwaelder, S.M., Fischer, T.H. and White 2nd, G.C. Rap1b is required for normal platelet function and hemostasis in mice. J. Clin. Invest. 115 (2005) 680-687. DOI: 10.1172/JCI22973.